Sigyn Therapeutics, Inc. (OTCMKTS:SIGY – Get Free Report)’s stock price dropped 24.6% on Friday . The company traded as low as $4.07 and last traded at $4.07. Approximately 325 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 629 shares. The stock had previously closed at $5.40.
Sigyn Therapeutics Stock Performance
The business’s fifty day moving average price is $5.41 and its 200-day moving average price is $5.42.
About Sigyn Therapeutics
Sigyn Therapeutics, Inc, a development-stage company, provides therapeutic solutions in the United States. Its lead product candidate is Sigyn Therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community acquired pneumonia, drug resistant bacterial infections, and emerging pandemic threats.
Recommended Stories
- Five stocks we like better than Sigyn Therapeutics
- What does consumer price index measure?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- How to Calculate Stock Profit
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for Sigyn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigyn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
